Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immunovant, Inc.NASDAQ: IMVT
Research & Development · Q2 FY2027 · quarter ended Sep 2026
Research & development dips below year-ago levels
Q2 FY2027 research & development of $85.01M fell 25.6% year over year, behind the +16.2% change in trailing-twelve-month research & development. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at +41.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.6% toward the trailing-twelve-month pace of +16.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 456.66M USD
- Year-over-year change
- +26.5%
- 4-year CAGR
- +45.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 456.66M | +26.5% |
| FY2025 | 2025-03-31 | 360.92M | +69.5% |
| FY2024 | 2024-03-31 | 212.93M | +32.9% |
| FY2023 | 2023-03-31 | 160.26M | +57.4% |
| FY2022 | 2022-03-31 | 101.81M | — |
Research & Development vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 research & development of $468.85M is the highest of the 11 companies compared; the peer median is $145.31M.
- Its year-over-year change of +16.2% is the 7th highest of 11, against a peer median of +19.9%.
- Research & development amounts to 6608.2% of revenue for IMVT, versus a peer median of 41.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
| LTM Mar 2026 | $360.26M | +137.9% | +38.9% | — | |
| LTM Sep 2026 | $236.22M | +65.3% | +8.5% | 26.3% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $151.01M | +44.8% | +53.7% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
| Peer median (excluding IMVT) | $145.31M | +19.9% | +15.3% | 41.9% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.